Payment overview · 2025
General Payments
$3,863.60
131 reported records · 30 companies
Healthcare provider profile · identity verified
Wilbert B Maniego, MD
Allopathic & Osteopathic Physicians|Internal Medicine · NEW HYDE PARK, NY · NPI 1356392427
Verified facts
What the public records show
CMS Open Payments records show Wilbert B Maniego, MD received $3,863.60 in general payments during 2025 across 131 reported records.
SANOFI-AVENTIS U.S. LLC accounted for 17.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 45 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Myrbetriq, Ozempic, Synthroid, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Prolia by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 184 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $659.13 | 17.1% | 6 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $513.70 | 13.3% | 21 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $423.62 | 11.0% | 10 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $290.85 | 7.5% | 16 | 2025 |
| CeQur Corporation | Unresolved — no canonical attribution shown | $226.80 | 5.9% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $182.79 | 4.7% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $153.56 | 4.0% | 7 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $136.90 | 3.5% | 8 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $127.03 | 3.3% | 8 | 2025 |
| Vifor Pharma, Inc. | Unresolved — no canonical attribution shown | $122.02 | 3.2% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $114.88 | 3.0% | 5 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $111.98 | 2.9% | 7 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $111.16 | 2.9% | 6 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $109.92 | 2.9% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $84.00 | 2.2% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $80.55 | 2.1% | 4 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $55.27 | 1.4% | 2 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $46.99 | 1.2% | 2 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $43.08 | 1.1% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $42.14 | 1.1% | 3 | 2025 |
| MEDICOMP INC | Unresolved — no canonical attribution shown | $37.71 | 1.0% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $24.98 | 0.7% | 1 | 2025 |
| Renalytix AI, Inc. | Unresolved — no canonical attribution shown | $24.26 | 0.6% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $22.97 | 0.6% | 1 | 2025 |
| SCPHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $22.64 | 0.6% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $22.57 | 0.6% | 1 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $22.31 | 0.6% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $20.60 | 0.5% | 1 | 2025 |
| Ionis Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.22 | 0.4% | 1 | 2025 |
| Medicure Pharma Inc. | Unresolved — no canonical attribution shown | $13.97 | 0.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $3,863.60 | 131 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $659.13 | 6 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $372.89 | 13 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $249.51 | 8 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $248.28 | 6 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $241.10 | 13 | 2025 |
Source payment records
|
|||||
| CeQur Simplicity Normalized: cequr simplicity |
Device | CeQur Corporation | $226.80 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $175.34 | 4 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $153.56 | 7 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $136.90 | 8 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $123.28 | 5 | 2025 |
Source payment records
|
|||||
| Veltassa Normalized: veltassa |
Drug | Vifor Pharma, Inc. | $122.02 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $121.98 | 7 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $114.88 | 5 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $111.98 | 7 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $109.92 | 4 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $95.01 | 5 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $60.31 | 4 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $55.27 | 2 | 2025 |
Source payment records
|
|||||
| Brinsupri Normalized: brinsupri |
Drug | Insmed, Inc. | $55.27 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $49.75 | 3 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $49.75 | 3 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $46.99 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $43.78 | 2 | 2025 |
Source payment records
|
|||||
| UNITHROID Normalized: unithroid |
Drug | Amneal Pharmaceuticals LLC | $43.08 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $42.14 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $42.14 | 3 | 2025 |
Source payment records
|
|||||
| TELEPATCH CARDIAC MONITOR Normalized: telepatch cardiac monitor |
Device | MEDICOMP INC | $37.71 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $24.98 | 1 | 2025 |
Source payment records
|
|||||
| KIDNEYINTELX BLOOD COLLECTION CONVENIENCE KIT Normalized: kidneyintelx blood collection convenience kit |
Device | Renalytix AI, Inc. | $24.26 | 1 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $23.79 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $22.97 | 1 | 2025 |
Source payment records
|
|||||
| FUROSCIX Normalized: furoscix |
Drug | SCPHARMACEUTICALS INC. | $22.64 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $22.57 | 1 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $22.31 | 1 | 2025 |
Source payment records
|
|||||
| FLUZONE HIGH-DOSE Normalized: fluzone high dose |
Biological | SANOFI PASTEUR INC. | $22.31 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $22.30 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $22.30 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $20.60 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $19.99 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $19.38 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $18.83 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $17.92 | 1 | 2025 |
Source payment records
|
|||||
| Myrbetriq Normalized: myrbetriq |
Drug | Astellas Pharma US Inc | $16.15 | 1 | 2025 |
Source payment records
|
|||||
| TRYNGOLZA Normalized: tryngolza |
Drug | Ionis Pharmaceuticals, Inc. | $15.22 | 1 | 2025 |
Source payment records
|
|||||
| Zypitamag Normalized: zypitamag |
Drug | Medicure Pharma Inc. | $13.97 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 184 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 63 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 71 | exact normalized | Medicare Part D |
| Myrbetriq myrbetriq |
2025 | Myrbetriq | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 39 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
19 | 12 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
63 | 21 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
71 | 20 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
71 | 20 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
184 | 28 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 534 | 149 |
| Losartan Potassium | Losartan Potassium | 414 | 122 |
| Atorvastatin Calcium | Atorvastatin Calcium | 366 | 122 |
| Simvastatin | Simvastatin | 364 | 98 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 311 | 99 |
| Levothyroxine Sodium | Levothyroxine Sodium | 299 | 70 |
| Metformin Hcl | Metformin Hcl | 288 | 92 |
| Gabapentin | Gabapentin | 189 | 60 |
| Lisinopril | Lisinopril | 185 | 42 |
| Eliquis | Apixaban | 184 | 28 |
| Metoprolol Succinate | Metoprolol Succinate | 173 | 52 |
| Allopurinol | Allopurinol | 146 | 41 |
| Metoprolol Tartrate | Metoprolol Tartrate | 137 | 40 |
| Tamsulosin Hcl | Tamsulosin Hcl | 132 | 43 |
| Carvedilol | Carvedilol | 122 | 28 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 116 | 38 |
| Pantoprazole Sodium | Pantoprazole Sodium | 115 | 57 |
| Furosemide | Furosemide | 113 | 24 |
| Pravastatin Sodium | Pravastatin Sodium | 113 | 35 |
| Meloxicam | Meloxicam | 105 | 73 |
| Glipizide | Glipizide | 96 | 27 |
| Montelukast Sodium | Montelukast Sodium | 95 | 39 |
| Mirtazapine | Mirtazapine | 91 | 22 |
| Fenofibrate | Fenofibrate | 90 | 24 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 86 | 26 |
| Finasteride | Finasteride | 80 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 79 | 43 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 77 | 35 |
| Glipizide Er | Glipizide | 76 | 22 |
| Atenolol | Atenolol | 74 | 20 |
| Famotidine | Famotidine | 73 | 34 |
| Jardiance | Empagliflozin | 71 | 20 |
| Donepezil Hcl | Donepezil Hcl | 70 | 19 |
| Memantine Hcl | Memantine Hcl | 70 | 15 |
| Alendronate Sodium | Alendronate Sodium | 69 | 21 |
| Doxycycline Hyclate | Doxycycline Hyclate | 68 | 57 |
| Potassium Chloride | Potassium Chloride | 65 | 21 |
| Zolpidem Tartrate | Zolpidem Tartrate | 65 | 17 |
| Spironolactone | Spironolactone | 64 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 63 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 63 | 23 |
| Farxiga | Dapagliflozin Propanediol | 63 | 21 |
| Warfarin Sodium | Warfarin Sodium | 63 | suppressed |
| Azithromycin | Azithromycin | 60 | 50 |
| Januvia | Sitagliptin Phosphate | 58 | 17 |
| Omeprazole | Omeprazole | 58 | 21 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 57 | 18 |
| Fluticasone Propionate | Fluticasone Propionate | 56 | 37 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 52 | 12 |
| Repaglinide | Repaglinide | 52 | 17 |
| Diclofenac Sodium | Diclofenac Sodium | 48 | 22 |
| Ezetimibe | Ezetimibe | 48 | 13 |
| Telmisartan | Telmisartan | 48 | 13 |
| Oxycodone Hcl | Oxycodone Hcl | 46 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 44 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 44 | 38 |
| Hydrochlorothiazide | Hydrochlorothiazide | 43 | 13 |
| Latanoprost | Latanoprost | 41 | suppressed |
| Synthroid | Levothyroxine Sodium | 39 | suppressed |
| Folic Acid | Folic Acid | 37 | 12 |
| Prednisone | Prednisone | 35 | 25 |
| Metformin Hcl Er | Metformin Hcl | 34 | 11 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 33 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 33 | suppressed |
| Nifedipine Er | Nifedipine | 32 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 31 | 19 |
| Cefuroxime | Cefuroxime Axetil | 31 | 28 |
| Divalproex Sodium | Divalproex Sodium | 31 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 31 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 30 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 28 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 27 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 26 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 25 | suppressed |
| Valsartan | Valsartan | 25 | suppressed |
| Vascepa | Icosapent Ethyl | 25 | 12 |
| Silver Sulfadiazine | Silver Sulfadiazine | 24 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 23 | suppressed |
| Irbesartan | Irbesartan | 23 | suppressed |
| Mupirocin | Mupirocin | 23 | 12 |
| Ozempic | Semaglutide | 23 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 23 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 22 | 16 |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 22 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 21 | suppressed |
| Levetiracetam | Levetiracetam | 21 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 21 | suppressed |
| Fluconazole | Fluconazole | 20 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 20 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 20 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 20 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 20 | 19 |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 19 | suppressed |
| Ibuprofen | Ibuprofen | 19 | 11 |
| Prolia | Denosumab | 19 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 19 | suppressed |
| Alprazolam | Alprazolam | 18 | suppressed |
| Anastrozole | Anastrozole | 18 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Lorazepam | Lorazepam | 18 | suppressed |
| Myrbetriq | Mirabegron | 18 | suppressed |
| Tradjenta | Linagliptin | 18 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 17 | suppressed |
| Baclofen | Baclofen | 16 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Ketoconazole | Ketoconazole | 16 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 15 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 15 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 15 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 14 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 14 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 13 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 13 | suppressed |
| Xarelto | Rivaroxaban | 13 | suppressed |
| Diclofenac Sodium Er | Diclofenac Sodium | 12 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 12 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 12 | suppressed |
| Betimol | Timolol | 11 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 11 | suppressed |
| Celecoxib | Celecoxib | 11 | suppressed |
| Felodipine Er | Felodipine | 11 | suppressed |
| Hydroxyurea | Hydroxyurea | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,863.60 · 131 records | SANOFI-AVENTIS U.S. LLC | AIRSUPRA, AREXVY, Arikayce, BREZTRI, Brinsupri, CREON, CeQur Simplicity, Cologuard Collection Kit, ELIQUIS, EVENITY, FARXIGA, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, FLUZONE HIGH-DOSE, FREESTYLE LIBRE 3, FUROSCIX, GEMTESA, GVOKE HYPOPEN, INGREZZA, JARDIANCE, KIDNEYINTELX BLOOD COLLECTION CONVENIENCE KIT, Kerendia, LEQVIO, LINZESS, Leqembi, MOUNJARO, Myrbetriq, NEXLETOL, NURTEC ODT, OTEZLA, Ozempic, QULIPTA, REPATHA, SHINGRIX, SYNTHROID, TELEPATCH CARDIAC MONITOR, TRELEGY ELLIPTA, TRYNGOLZA, TZIELD, UBRELVY, UNITHROID, VRAYLAR, Veltassa, Veozah, XIFAXAN, Zypitamag | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error